Effective October 1, 2008, OrthoLogic Corp. began doing business as Capstone Therapeutics (the "Company"); on May 21, 2010 the name of the Company was changed from OrthoLogic Corp. to Capstone Therapeutics Corp. The OTCQB ticker symbol is "CAPS" and the website is www.capstonethx.com.Capstone Therapeutics Corp. (formerly OrthoLogic Corp.) is a biotechnology company committed to developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company was focused on development and commercialization of two product platforms: AZX100 and Chrysalin (rusalatide acetate or TP508).AZX100 is a novel synthetic 24-amino acid peptide, one of a new class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis and the prevention of hypertrophic and keloid scarring. Capstone has an exclusive worldwide license to AZX100.Chrysalin, the Company's novel synthetic 23-amino acid peptide, has been proven in multiple pre-clinical and clinical models to stimulate cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It was evaluated in disorders that involve vascular endothelial dysfunction such as acute myocardial infarction and chronic myocardial ischemia.